These innovative compounds represent a significant progression in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose https://woodyknjq486296.blogprodesign.com/60333155/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide